To read the full story
Related Article
- Japan’s Revised Drug Distribution Guidelines Take Effect
March 4, 2024
ORGANIZATION
- JaDHA Creates Hypothetical Case Collection to Push Two-Stage Approval of SaMD
October 11, 2024
- EFPIA Chief Sees Positive Signal from Japan Policymakers, Calls for Consistency
October 11, 2024
- EFPIA Japan Chair Urges All Players to Join Forces in Drug Loss Fight
October 10, 2024
- New Administration Must Not Stop Efforts toward Bolstering Pharma Industry: JPMA Chief
October 9, 2024
- Pharma Labor Group Renews Call for Abolition of Off-year Revisions
October 9, 2024
It’s easy to spot motivated and engaged employees. They are more productive, they go the extra mile, and they display a sense of ownership in their work.But how do you replicate this culture throughout your organization? How do you encourage…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…